Quanterix Corporation · NASDAQ:QTRX
Quanterix — J.P. Morgan Healthcare Conference 2018
29 slides from Quanterix's conference presentation, January 2018
Slide 1: Kevin Hrusovsky Chairman & CEO
Kevin Hrusovsky Chairman & CEO January, 2018
Slide 2: Safe Harbor
Safe Harbor Forward-Looking Statements This presentation and the accompanying oral commentary contain “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include information conc
Slide 3: Management, Board and Investors
Marquis Management, Board and Investors Management Board Kevin Hrusovsky Chairman & CEO Martin Madaus, PhD Chairman & CEO Ortho Clinical Diagnostics Douglas Cole, MD Managing Partner Flagship Pioneering Kevin Hrusovsky Keith L. Crandell Co-Founder & Managing Director ARCH Venture Chairman & CEO John
Slide 4: Disruptive Biomarker Technology Enabling Precision Health
Disruptive Biomarker Technology Enabling Precision Health Digital Sensitivity Multiple Instrument Formats Possible See Health and Disease Processes Earlier Analog Digital Competition Multiple Target Markets Less Invasive Sample Types Research Diagnostics1 vs. Blood draw Biopsy Clinical trials1 Preci
Slide 5: Convergence of Technology and Healthcare
Convergence of Technology and Healthcare Measuring Life’s Variables digital biomarkers analog digital 5
Slide 6: Molecules of Life; Genotype to Phenotype
Molecules of Life; Genotype to Phenotype Measuring What Could Not Be Seen Before Molecules of Life 100,000+ proteins 20,000 RNA genes ELISA ng/mL ~1975-1990’s 900x ECL pg/mL ~2000-2013 Cancer Diabetes sensitivity increase fg/mL Quanterix ~2013-present Diet Sleep Exercise Stress Concussions Pollution
Slide 7: Preventative Healthcare
Preventative Healthcare sickness begins symptoms biomarker HEALTHCARE SICK CARE Placement of disease concentration categories is for Biopsy, illustration purposes only spinal tap cancer or other sick, invasive asymptomatic procedures neuro INVASIVENESS cardio infectious GOAL disease blood saliva uri
Slide 8: Preventative Healthcare: New Detection Limit
Preventative Healthcare sickness begins symptoms biomarker HEALTHCARE SICK CARE concentration biopsy spinal tap sick, asymptomatic Today Current detection ~205 limit INVASIVENESS Quanterix FDA-approved IA diagnostic tests <1,300 Proteins consistently detected by conventional IA tech New >100,000 ~10
Slide 9: Illuminating the Continuum from Health to Disease
Illuminating the Continuum from Health to Disease Sensitivity enables researchers to expand into diseases associated with previously undetectable proteins 20 pubs 89 pubs 75 pubs 36 markers 49 markers 95 markers Oncology Neuro Inflammation Infectious Disease Potential to be highly Potential for diag
Slide 10: Unprecedented Protein Detection Sensitivity
Unprecedented Protein Detection Sensitivity Normal clinical range (median) Quanterix Leading ELISA LoD (2.5 SD) 1 LoD comparison Quanterix LoD (2.5 SD) Provider Protein Innotest Ab 42 Innotest Tau Techne IL‐6 Techne TNF‐α Assay ALPCO C‐peptide Techne IL‐10 Millipore INF‐α Genentech IL‐17A Roche/Siem
Slide 11: Applications
Applications Oncology Neurology Cardiology ID, Inflammation TOTALS: Other* DEATHS / YR 9MM 18MM 7MM 15MM ~50MM WW COST $350B $270B $470B $140B $1.3T BIOMARKER MARKET $25B $6B $9B $38B * Other includes validation related to inflammation, technology, immunology and others Source: Health Advances analy
Slide 12: Our Product Portfolio
Our Product Portfolio Instruments Assay kits Services HD-1 Analyzer - $175k list SR-X - $75k list Consumables and Ab’s In-house and field based Launched 2014 Launch 1H’18, Now Q1’18 80 assays kits including Sample testing and Assay Dev’l Fully-automated Reader only homebrew / multiplex
Slide 13: SR-X Pre-Launch Traction
SR-X Pre-Launch Traction - iy yj MYRIAD SANOFI REM MASSACHUSETTS GENERAL HosprraL = MIAMI LUND UNIVERSITY cid | “UCL * HOSPITAL GERMANS TRIAS I PUJOL, BADALONA JOHNs HOPKINS BA UNiversirye Mc DEMENTIA imag bene UNIVERSITY Y DENVER microcoat RESEARCH notics THE UNIVERSITY OF UNIVERSITY o, “NEW ENGLAN
Slide 14: Strategic Roadmap to $38B Market
Strategic Roadmap to $38B Market $11B $6B Mammography $4B Core Lab IA POC IA & $2B Companion Diagnostics Molecular $2B MS Monitoring Diagnostics and Health $1B PSA Monitoring Screens Risk/Reward $1B TBI Monitoring Pharma $30B $1B Alzheimer’s Diagnosis Services $1B Pancreatic Cancer Screening and Mon
Slide 15: $38B IVD Diagnostics, LDT and Health Screens
$38B IVD Diagnostics, LDT and Health Screens Disrupt healthcare Pharma Services, LDT, CDx Diagnostics Partners Reinvent drug Abbott and BioMerieux development Research Discover and Phase I, II and III validate digital Drug Trials biomarkers Clia Lab, Menu Global sales channel $3B Menu expansion Benc
Slide 16: Current Landscape Dominated by Few Companies
Current Landscape Dominated by Few Companies Complementary: IA + Nucleic Acid Y/E 2016 Nucleic Acid MASS SPECTROMETRY Installed Base: $2B 14,500 + Pharma Services $2B * 41% + 13% Future Expansion 5% $3B Indirect Competition: 3% IMAGING 2% IA Research 1% market: Other 15% $1B Manual 20% (7% CAGR) *Im
Slide 17: Rapid Growth with Compelling Consumable Pull-through
Rapid Growth with Compelling Consumable Pull-through Three-year Growth ($ in millions) 2018 Milestones Revenue • Q1: Launch SR-X benchtop Instruments 185 Publications 180 $22.5- • Q4: Launch HD-X: Trade in $22.9 Markers 176 • Expand menu by 30+ assays (cumulative) • Multiplexing, cost and sensitivit
Slide 18: Business Profile
Q4 represents a preliminary, unaudited est. of financial information. Business Profile We have not finalized the audit of our results of operations for the 3 months and year ended 12/31/17, which may identify items requiring adjustment to these unaudited financial results. Product Revenue Allocation
Slide 19: Biomarkers Clinical Utility is Transforming Drug Development
Biomarkers Clinical Utility is Transforming Drug Development Toxicity Cumulative Trials using QTRX: 4th Leading Cause of 750 Death in USA 210% 500 increase in 75 300 probability of drug approval 2015 2016 2017 Pipeline Efficacy Depression 62% Cancer, auto immune and inflammation and neurology Schizo
Slide 20: Blue Chip Customers
Blue Chip Customers Research Institutions Biopharma Other 20
Slide 21: Rapid Adoption with Early Evidence of High Utilization
Rapid Adoption with Early Evidence of High Utilization # of Instruments Consumable avg. $/yr./instr.1 $175,000 95% Homebrew $135,000 70% Neuro $100,000 30% Homebrew Today avg. is $52K per instr, Applications up from $40K Homebrew revenue per # of Instruments test is 1/3 kits Consumable avg. $117,000
Slide 22: Rapid growth of Clinical Trials in Oncology and Auto Immune
Rapid growth of Clinical Trials in Oncology and Auto Immune Oncology: Immunotherapy Type 2 Diabetes “75% of 500+ clinical trials Autoimmune Diseases Pulmonary require Quanterix data w/ Luminex” Cardiovascular Disease Neurological Ralph McDade, CEO RBM Myriad Genetics (45 Luminex Readers SR-X) Predic
Slide 23: Neurology Publications – Catalyze Disruption
Neurology Publications – Catalyze Disruption (36) JAMA Neurol Neurol Neuroinfl Sports/military/concussion 2016; Aug 2 2017; May 1 TBI NF-L NF-L Alzheimer's Disease 12 patients, 570 patients & HCs J Neurotraum Neurol. longitudinal study cross-sectional Multiple sclerosis 2016; Oct 1 (25) Neurodegener
Slide 24: Neurology Opportunity
Neurology Opportunity Multiple sclerosis Alzheimer's Disease Digital biomarkers impacting all areas of brain health: Guillain-Barre syndrome Frontotemporal Dementia Tau Amyotrophic Lateral Sclerosis (ALS) P-Tau Delirium Amyloid β 40 Amyloid β 42 Stroke Nf-L Traumatic brain injury BDNF Concussion GFA
Slide 25: Neurology Customers
Neurology Customers Instrument Sales ($) Number of Instruments (units) 48 4.3 35 2.8 1.9 17 2015 2016 2017E 2015 2016 2017E Consumables Sales ($) Consumable Markers Added Neuro Projects in Trials 4.8 8 22 1.9 1.6 3 1 3 6 2015 2016 2017E 2015 2016 2017E 2015 2016 2017E Accelerator Sales ($K) Accelera
Slide 26: Neurology Customers Pipeline
Q4 represents a preliminary, unaudited est. of financial information. We have not finalized the audit of our results of operations for the 3 Neurology Customers months and year ended 12/31/17, which may identify items requiring adjustment to these unaudited financial results. PIPELINE Instrument Sal
Slide 27: 6,500 Peer-Reviewed Publications
“40% lower cost, 60% more accessible, and live 8 years longer productive lives.” Kevin Hrusovsky Founder & Chair, Powering Precision Health Summit Revolutionary opportunities to detect earlier and improve treatment of: 606attendees 54 luminary speakers 18 corporate sponsors • Pancreatic Cancer • Con
Slide 28: Poised to Disrupt Healthcare and Create Significant Value
Poised to Disrupt Healthcare and Create Significant Value Differentiator Value Best in 1 Category-defining; Unrivaled Sensitivity Disrupt Class 2 $3B to New Methodical market penetration strategy to reward investors $38Bn1 Answers market 3 Genotype to phenotype; Drug Development to Dx Holy Grail 170
Slide 29: Empowering Personal Health Management Paradigm
Empowering Personal Health Management Paradigm * Subject to any required regulatory approvals and clearances, which the company has not applied for to date 29